Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (6260)	1/15/1999 1:40:00 AM
From: Vector1	Respond to of 9719

Steve, Great questions. They have delivered the first module of their machine. Module two will be delivered in Q2 and module III which includes the integrated software is scheduled before the end of the year. ABSC is not going after their own targets. They do get a low single digit royalty on compounds developed using their screening system. They have 400,000 compounds in house and an arrangement with Arqule for more. They have not yet built their own machine. When built they plan on using selling screening on a time share basis for smaller pharmas and biotechs. v1